EGFR and neoplasm: In in vitro models using NSCLC cell lines, Apicella et al. [171] showed that lactate is a key mediator of tumor cell resistance to therapy based on tyrosine kinase inhibitors (TKIs), particularly JNJ-605, a c-MET receptor tyrosine kinase inhibitor, and erlotinib, an epidermal growth factor receptor (EGFR) inhibitor [171].